Skip to Content

Prazosin Pregnancy and Breastfeeding Warnings

Prazosin is also known as: Minipress

Prazosin Pregnancy Warnings

Prazosin has been assigned to pregnancy category C by the FDA. Animal studies have shown evidence of decreased litter size after prazosin was administered at doses more than 225 times the maximum recommended dose in humans (on a per kg basis). No controlled data are available in human pregnancy, but studies in which prazosin was administered during human pregnancy show only maternal tachycardia and no teratogenic effects. Prazosin should only be given during pregnancy when benefit outweighs risk.

Use of prazosin combined with oxprenolol during human pregnancy has been reported. The population studied was 44 pregnant women, 25 of whom had severe hypertension, and 19 of whom had severe hypertension, edema, and proteinuria. There were three intrauterine deaths that were considered related to underlying diseases and not to drug therapy. One infant who suffered intrauterine growth retardation died postpartum after elective Cesarean section at 27 weeks gestation. This growth retardation was an expected finding given the underlying condition of the mother and the population studied. The overall fetal survival rate of 78% was considered acceptable relative to untreated hypertensive pregnancy fetal survival rates. In short, no definite causative connection has been made between adverse sequelae to the fetus and prazosin.

See references

Prazosin Breastfeeding Warnings

The manufacturer states that small amounts of prazosin are excreted into human milk. The manufacturer recommends that caution be used when administering prazosin to nursing women.

See references

References for pregnancy information

  1. Venuto R, Burstein P, Schneider R "Phenochromocytoma: antepartum diagnosis and management with tumor resection in the puerperium." Am J Obstet Gynecol 150 (1984): 431-2
  2. Hellstrom WJG, Wang R, Peterson CA, Varady JC, Gesundheit N, Sikka SC "Effects of alprostadil and prazosin on motility, viability and membrane integrity of human sperm." J Urol 159 (1998): 1559-62
  3. "Product Information. Minipress (prazosin)." Pfizer US Pharmaceuticals, New York, NY.
  4. Lubbe WF, Hodge JV "Combined a- and B-adrenoceptor antagonism with prazosin and oxprenolol in control of severe hypertension in pregnancy." N Z Med J 94 (1981): 169-72

References for breastfeeding information

  1. "Product Information. Minipress (prazosin)." Pfizer US Pharmaceuticals, New York, NY.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.